Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

• Rui Wang,
• Antoine Italiano,
• Shubham Pant,
• Johann De Bono,
• Todd M Bauer,
• Christophe Massard,
• Chia-Chi Lin,
• Roberto Iacovelli,
• Martin Gutierrez,
• Mansoor Saleh,
• Helen Lee,
• Gennaro Daniele,
• Paolo Andrea Zucali,
• Marielle Chiron,
• Bradley C Carthon,
• Robin Meng,
• Giovanni Abbadessa,
• Marcello Tucci,
• Wu-Chou Su,
• Alastair Greystoke,
• Ying-Chun Shen,
• Matteo Perrino,
• Yingwen Dong,
• Laure Loumagne,
• Lucie Lépine

Affiliations

Rui Wang

Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China

Antoine Italiano

10 Department of Medical Oncology, Institute Bergonie, Bordeaux, Aquitaine, France

Shubham Pant

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Johann De Bono

Institute of Cancer Research, London, UK

Todd M Bauer

Aff5 0000 0004 0459 5478grid.419513.bSarah Cannon Research Institute/Tennessee Oncology, PLLC 37203 Nashville TN USA

Christophe Massard

5Institut de Cancérologie Gustave Roussy, Villejuif, France

Chia-Chi Lin

4 National Taiwan University Hospital, Taipei, Taiwan

Roberto Iacovelli

3 Department of Oncology, Catholic University of the Sacred Heart, “Agostino Gemelli” School of Medicine, Rome, Italy, Rome, Italy

Martin Gutierrez

Hackensack University Medical Center, Hackensack, New Jersey, USA

Mansoor Saleh

Department of Medicine, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA

Helen Lee

2Royal National Institute of Blind People, London, UK

Gennaro Daniele

Direzione Scientifica, Fondazione Policlinico Universitario A Gemelli IRCCS, Roma, Italy

Paolo Andrea Zucali

Department of Oncology, Humanitas Clinical and Research Center, IRCCS, Milan, Italy

Marielle Chiron

Translational and Experimental Medicine, Sanofi Research & Development, Vitry-sur-Seine, France

Bradley C Carthon

Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Robin Meng

1Sanofi, Cambridge, USA

Giovanni Abbadessa

1Sanofi, Cambridge, USA

Marcello Tucci

12 Division of Oncology, Cardinal Massaia Hospital, Asti, Italy

Wu-Chou Su

Division of Oncology, Department of Internal Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan

Alastair Greystoke

Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK

Ying-Chun Shen

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

Matteo Perrino

Department of Biomedical Sciences, IRCCS Istituto Clinico Humanitas, Rozzano, Italy

Yingwen Dong

Biostatistics Oncology Late Phase, Sanofi, Cambridge, Massachusetts, USA

Laure Loumagne

Translational Medicine, Sanofi-Aventis, Paris, France

Lucie Lépine

Pharmacokinetics, Excelya on behalf of Sanofi, Alfortville, France